药易购(300937) - 2024 Q4 - 年度业绩预告

Financial Performance - The estimated net profit for 2024 is projected to be between 14.5 million and 19.5 million RMB, representing a decline of 67.24% compared to the previous year's profit of 59.53 million RMB [3]. - The net profit after deducting non-recurring gains and losses is expected to be between 8.75 million and 12.75 million RMB, a decrease of 76.40% to 83.81% from last year's profit of 54.03 million RMB [3]. - The decline in performance is primarily attributed to a decrease in gross profit margin due to reduced market demand in the pharmaceutical wholesale industry [5]. Business Strategy - The company is focusing on expanding its second growth curve, with investments in team building, management system upgrades, talent development, and research and development [5]. - The new business initiatives are still in the cultivation phase, and the realization of profitability will require more time [5]. Communication and Reporting - The company has communicated with its auditing firm regarding the performance forecast, and there are no significant discrepancies [4]. - The specific operational data will be detailed in the company's 2024 annual report [6]. - The company emphasizes the importance of cautious decision-making and awareness of investment risks [7].